Literature DB >> 16208713

What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?

Udaya S Tantry, Kevin P Bliden, Paul A Gurbel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16208713     DOI： 10.1002/ccd.20526

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN： 1522-1946            Impact factor:   2.692


× No keyword cloud information.
  2 in total

1.  State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.

Authors:  Dharam J Kumbhani; Steven P Marso; Carlos A Alvarez; Darren K McGuire
Journal:  Curr Cardiovasc Risk Rep       Date:  2015-01

2.  Residual platelet reactivity is preferred over platelet inhibition rate in monitoring antiplatelet efficacy: insights using thrombelastography.

Authors:  Hong-Yi Wu; Chi Zhang; Xin Zhao; Ju-Ying Qian; Qi-Bing Wang; Jun-Bo Ge
Journal:  Acta Pharmacol Sin       Date:  2019-09-12       Impact factor: 6.150
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.